Type 1 Diabetes TrialNet Clinical Network Hub

项目摘要/摘要 TrialNet的使命是将疾病修改疗法应用于1型糖尿病(T1D)的临床应用 侧重于在疾病的早期阶段进行临床试验，以预防或推迟临床发作。TrialNet是一种 由25个临床中心和数百个附属机构组成的国际联盟，分布在美国、加拿大、英国、 瑞典、芬兰、德国、意大利和澳大利亚。这些网站与TrialNet协调中心一起 (TNCC)、TrialNet临床中心(HUB)和我们的协作力学研究小组(CMSP)的成员， (A)进行自然病史研究，以描述T1D的进展，并确定个人进行临床试验； (B)在临床诊断之前和之后进行疾病修正疗法的临床试验；和(C)增加 通过涉及TrialNet内部和外部调查人员的机械性研究来评估试验的科学价值。 1型糖尿病试验网络中心的使命是通过以下方式提高关键网络活动的效率 支持协作和创新的方法进行筛选、招聘、保留、试验开发和 执行和传播成果。 在上一次赠款期间取得了相当大的成功，这份申请描述了我们继续下去的建议 作为糖尿病试验网络的临床中心。我们侧重于三个领域；活动：(A)加强风险筛选 确定高危个体，(B)加强临床试验的登记和保留，以及(C)加强临床试验 政府有效地实施TrialNet的目标。

PROJECT SUMMARY / ABSTRACT TrialNet's mission is to bring disease modifying therapy to clinical use in type 1 diabetes (T1D) with a primary focus on conducting clinical trials at early stages of disease to prevent or delay clinical onset. TrialNet is an international consortium of twenty-five Clinical Centers and hundreds of Affiliate sites in US, Canada, UK, Sweden, Finland, Germany, Italy, and Australia. These sites together with the TrialNet Coordinating Center (TNCC), the TrialNet Clinical Hub (HUB), and members of our Collaborative Mechanistic Studies Panel (CMSP), (a) conduct natural history studies to describe the progression of T1D and identify individuals for clinical trials, (b) conduct clinical trials of disease modifying therapy both prior to and after clinical diagnosis, and (c) increase the scientific value of trials through mechanistic studies involving investigators within and external to TrialNet. The mission of the Type 1 Diabetes TrialNet Hub is to increase the efficiency of critical Network activities by supporting collaborative and innovative approaches for screening, recruitment, retention, trial development and implementation, and dissemination of results. With considerable success during the previous grant period, this application describes our proposal to continue to serve as the Diabetes TrialNet Clinical HUB. We focus on three areas; activities to (a) enhance risk screening to identify at-risk individuals, (b) enhance enrollment and retention in clinical trials, and (c) enhance clinical administration to effectively implement TrialNet's goals.